Literature DB >> 28420824

Dynamic changes in near-infrared spectroscopy (NIRS) findings in first-episode schizophrenia: a case report.

Tsuyoshi Hatakeyama1, Yasuto Kunii1,2, Itaru Miura1, Shuntaro Itagaki1, Soichi Kono1, Tetsuya Shiga1, Sachie Oshima1, Keiko Nozaki1, Rieko Suzuki1, Hirooki Yabe1.   

Abstract

The clinical course of schizophrenia is characterized by recurrence and chronicity and has a large burden on society. Nevertheless, diagnosis of schizophrenia is based only on distinctive symptoms and the disease course. Near-infrared spectroscopy (NIRS) is a useful method for measuring changes in the hemoglobin concentration in the cortical surface area and reflects brain function. We measured NIRS four times during the clinical course in a patient with first-episode schizophrenia.A 17-year-old woman admitted to our hospital because of hallucinations, delusions and appetite loss. After treatment with low-dose antipsychotics, NIRS findings showed a prompt increase in the cerebral blood volume in the frontal region. On the basis of the clinical course of this patient, we introduce a new point of view, namely, that NIRS findings may be useful as a state marker that indicates the severity of schizophrenia in some cases.

Entities:  

Keywords:  biomarker; homovanillic acid; near-infrared spectroscopy; schizophrenia; state marker

Mesh:

Substances:

Year:  2017        PMID: 28420824      PMCID: PMC5476820          DOI: 10.5387/fms.2016-22

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  8 in total

1.  Differential spatiotemporal characteristics of the prefrontal hemodynamic response and their association with functional impairment in schizophrenia and major depression.

Authors:  Masaru Kinou; Ryu Takizawa; Kohei Marumo; Shingo Kawasaki; Yuki Kawakubo; Masato Fukuda; Kiyoto Kasai
Journal:  Schizophr Res       Date:  2013-09-07       Impact factor: 4.939

2.  Frontal lobe function and social adjustment in patients with schizophrenia: near-infrared spectroscopy.

Authors:  Yoshinori Watanabe; Takahiro Urakami; Seiji Hongo; Tenpei Ohtsubo
Journal:  Hum Psychopharmacol       Date:  2014-11-19       Impact factor: 1.672

3.  Normalization of frontal cerebral perfusion in remitted elderly major depression: a 12-month follow-up SPECT study.

Authors:  Víctor Navarro; Cristóbal Gastó; Francisco Lomeña; José J Mateos; Teodoro Marcos; María J Portella
Journal:  Neuroimage       Date:  2002-07       Impact factor: 6.556

4.  Neuroimaging-aided differential diagnosis of the depressive state.

Authors:  Ryu Takizawa; Masato Fukuda; Shingo Kawasaki; Kiyoto Kasai; Masaru Mimura; Shenghong Pu; Takamasa Noda; Shin-Ichi Niwa; Yuji Okazaki
Journal:  Neuroimage       Date:  2013-06-10       Impact factor: 6.556

5.  Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive brain activation study.

Authors:  Tomohiro Suto; Masato Fukuda; Makoto Ito; Toru Uehara; Masahiko Mikuni
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

6.  A longitudinal functional neuroimaging study in medication-naïve depression after antidepressant treatment.

Authors:  Hiroi Tomioka; Bun Yamagata; Shingo Kawasaki; Shenghong Pu; Akira Iwanami; Jinichi Hirano; Kazuyuki Nakagome; Masaru Mimura
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

7.  Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study.

Authors:  Joji Nishimura; Shingo Kakeda; Osamu Abe; Reiji Yoshimura; Keita Watanabe; Naoki Goto; Hikaru Hori; Toru Sato; Hidemasa Takao; Hiroyuki Kabasawa; Jun Nakamura; Yukunori Korogi
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-08       Impact factor: 2.570

Review 8.  Near-infrared spectroscopy in schizophrenia: a possible biomarker for predicting clinical outcome and treatment response.

Authors:  Shinsuke Koike; Yukika Nishimura; Ryu Takizawa; Noriaki Yahata; Kiyoto Kasai
Journal:  Front Psychiatry       Date:  2013-11-14       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.